Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Income from Continuing Operations: 2010-2024

Historic Income from Continuing Operations for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$95.1 million.

  • Altimmune's Income from Continuing Operations rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 18.82%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • Per Altimmune's latest filing, its Income from Continuing Operations stood at -$95.1 million for FY2024, which was down 7.53% from -$88.4 million recorded in FY2023.
  • In the past 5 years, Altimmune's Income from Continuing Operations registered a high of -$49.0 million during FY2020, and its lowest value of -$97.1 million during FY2021.
  • Over the past 3 years, Altimmune's median Income from Continuing Operations value was -$88.4 million (recorded in 2023), while the average stood at -$89.4 million.
  • Per our database at Business Quant, Altimmune's Income from Continuing Operations plummeted by 139.01% in 2020 and then increased by 12.75% in 2022.
  • Altimmune's Income from Continuing Operations (Yearly) stood at -$49.0 million in 2020, then tumbled by 97.96% to -$97.1 million in 2021, then climbed by 12.75% to -$84.7 million in 2022, then decreased by 4.41% to -$88.4 million in 2023, then dropped by 7.53% to -$95.1 million in 2024.